These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

80 related items for PubMed ID: 4047463

  • 1. [Epidemiologic study of peripheral obstructive arteriopathies: clinical effects of treatment with buflomedil chlorhydrate (Loftyl). Processing of data furnished by a polycenter study].
    Minerva Med; 1985 Oct 13; 76(39):1803-11. PubMed ID: 4047463
    [Abstract] [Full Text] [Related]

  • 2. [Action and tolerability of delayed-action buflomedil in obliterating arteriopathies of the lower limbs. A multicenter study].
    Andreozzi GM, Lepore R.
    Clin Ter; 1990 Nov 30; 135(4):273-81. PubMed ID: 2150026
    [Abstract] [Full Text] [Related]

  • 3. [Buflomedil in the treatment of chronic peripheral arterial diseases. Case contribution].
    Visconti W, Grillo N.
    Minerva Med; 1985 May 12; 76(19-20):945-53. PubMed ID: 3158842
    [Abstract] [Full Text] [Related]

  • 4. Oral buflomedil in the prevention of cardiovascular events in patients with peripheral arterial obstructive disease: a randomized, placebo-controlled, 4-year study.
    Limbs International Medicinal Buflomedil (LIMB) Study Group, Leizorovicz A, Becker F.
    Circulation; 2008 Feb 12; 117(6):816-22. PubMed ID: 18212283
    [Abstract] [Full Text] [Related]

  • 5. Double-blind placebo-controlled trial of buflomedil in intermittent claudication.
    Fonseca V, Mikhailidis DP, Barradas MA, Jeremy JY, Gracey L, Dandona P.
    Int J Clin Pharmacol Res; 1988 Feb 12; 8(5):377-81. PubMed ID: 3229875
    [Abstract] [Full Text] [Related]

  • 6. [Effects of buflomedil on peripheral arteriopathies. An open clinical study].
    Longo FN, Potortì F, Urbano O, Perroni GB.
    Minerva Cardioangiol; 1988 May 12; 36(5):249-52. PubMed ID: 3059229
    [No Abstract] [Full Text] [Related]

  • 7. [Buflomedil in arterial occlusive disease. Results of a controlled study].
    Trübestein G, Balzer K, Bisler H, Klüken N, Mahfoud Y, Müller-Wiefel H, Unkel B, Ziegler W.
    Dtsch Med Wochenschr; 1982 Dec 24; 107(51-52):1957-61. PubMed ID: 6756854
    [No Abstract] [Full Text] [Related]

  • 8. Clinical and hemorheological effects of buflomedil in diabetic subjects with intermittent claudication.
    Diamantopoulos EJ, Grigoriadou M, Ifanti G, Raptis SA.
    Int Angiol; 2001 Dec 24; 20(4):337-44. PubMed ID: 11782701
    [Abstract] [Full Text] [Related]

  • 9. [Multicenter study on the therapeutic activity of buflomedil chlorhydrate in obliterative arteriopathies of the legs].
    Allegra C, Andreozzi GM, Avellone G, Cospite M, Del Guercio R, Lepore R, Nuzzaci G, Pinto A, Romeo S.
    Clin Ter; 1986 Oct 15; 119(1):25-33. PubMed ID: 3539466
    [No Abstract] [Full Text] [Related]

  • 10. Buflomedil in arterial occlusive disease: results of a controlled multicenter study.
    Trübestein G, Balzer K, Bisler H, Klüken N, Muller-Wiefel H, Unkel B, Mahfoud Y, Ziegler W.
    Angiology; 1984 Aug 15; 35(8):500-5. PubMed ID: 6383127
    [Abstract] [Full Text] [Related]

  • 11. [Vascular and hemorheologic effects of buflomedil chlorhydrate in chronic obliterative arteriopathies of the legs].
    Coglitore S, Manganaro A, Barbera MC, Cento D, Buda D, Arrigo F, Consolo F.
    Minerva Cardioangiol; 1986 Nov 15; 34(11):745-9. PubMed ID: 2949163
    [No Abstract] [Full Text] [Related]

  • 12. [Evaluation of cutaneous necrosis risk in peripheral arterial diseases].
    D'Eri A, Martini R, Cordova RM, Trevisan G, Andreozzi GM.
    Minerva Cardioangiol; 2002 Jun 15; 50(3):239-44. PubMed ID: 12107403
    [Abstract] [Full Text] [Related]

  • 13. Letter by De Backer et al regarding article, "Oral buflomedil in the prevention of cardiovascular events in patients with peripheral arterial obstructive disease: a randomized, placebo-controlled, 4-year study".
    De Backer TL, Vander Stichele RH, Van Bortel LM.
    Circulation; 2008 Sep 02; 118(10):e151. PubMed ID: 18765384
    [No Abstract] [Full Text] [Related]

  • 14. A placebo-controlled study of the effects of intravenous Buflomedil on foot skin microcirculation in patients with severe intermittent claudication.
    Van den Brande P, Maurel A.
    Angiology; 1998 Feb 02; 49(2):105-14. PubMed ID: 9482510
    [Abstract] [Full Text] [Related]

  • 15. Positive effect of oral buflomedil on exercise-induced haemorheological damage and on claudication distance in peripheral obliterative arterial disease patients.
    Forconi S, Pieragalli D, Acciavatti A, Del Bigo C, Galigani C, Ralli L, Guerrini M, Di Perri T.
    J Int Med Res; 1984 Feb 02; 12(3):188-92. PubMed ID: 6734922
    [No Abstract] [Full Text] [Related]

  • 16. [Effects of the administration of buflomedil-hydrochloride on the arterial circulation of the legs in patients with obliterative arteriopathies].
    Tallarida G, Baldoni F, Peruzzi G, Raimondi G, Grimaldi I, Visigalli G, Gristina S, Massaro M, De Martinis L, Sangiorgi M.
    Cardiologia; 1983 Aug 02; 28(8):651-60. PubMed ID: 6687209
    [No Abstract] [Full Text] [Related]

  • 17. [Survey on adherence to hygiene and dietary rules in patients with arterial occlusive disease].
    Aligne C, Mosnier M, Mistretta F, Larguier JS.
    J Mal Vasc; 2000 Jun 02; 25(3):187-94. PubMed ID: 10906634
    [Abstract] [Full Text] [Related]

  • 18. [Factors determining late patency of aortobifemoral bypass graft].
    Davidović LB, Lotina SI, Kostić DM, Cinara II, Cvetković SD, Stojanov PL, Velimirović DB, Marković MM, Pejkić SA, Vukotić AM.
    Srp Arh Celok Lek; 1997 Jun 02; 125(1-2):24-35. PubMed ID: 17974352
    [Abstract] [Full Text] [Related]

  • 19. Effects of a 4-week treatment with prostaglandin E1 on plasma endothelin-1 release in patients with intermittent claudication.
    Mangiafico RA, Malatino LS, Santonocito M, Messina R, Attinà T, Dell'Arte S, Sarnataro F.
    Int J Clin Pharmacol Ther; 1999 Jul 02; 37(7):347-51. PubMed ID: 10442509
    [Abstract] [Full Text] [Related]

  • 20. [Flowmetric, thermometric and rheologic studies in obliterating arterial diseases of the lower extremities treated with buflomedil].
    Dorigo B, Raspanti D, Trapani M, Albanese B, Cameli AM, Digiesi V.
    Minerva Med; 1985 Feb 25; 76(7):269-75. PubMed ID: 3974940
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.